In contrast, in the two groups of AML patients separated by serum metabolomics, there were no significant differences in the expression rates of CD34, CD13, CD33, CD15, or CD117 antigens (Figure 5, Supplementary Figure.S1). The gene discussed is KIT; the disease is acute myeloid leukemia.